PUTTINI, MIRIAM
 Distribuzione geografica
Continente #
NA - Nord America 1.242
EU - Europa 523
AS - Asia 139
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
SA - Sud America 1
Totale 1.910
Nazione #
US - Stati Uniti d'America 1.221
DE - Germania 149
CN - Cina 95
SE - Svezia 77
UA - Ucraina 72
IE - Irlanda 68
IT - Italia 63
GB - Regno Unito 27
CA - Canada 21
HK - Hong Kong 19
BE - Belgio 15
DK - Danimarca 15
FI - Finlandia 15
IN - India 12
SG - Singapore 7
RU - Federazione Russa 6
IR - Iran 3
NL - Olanda 3
RO - Romania 3
AT - Austria 2
EU - Europa 2
FR - Francia 2
TR - Turchia 2
BR - Brasile 1
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
LU - Lussemburgo 1
MY - Malesia 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
Totale 1.910
Città #
Ann Arbor 370
Woodbridge 134
Chandler 96
Fairfield 92
Wilmington 85
Frankfurt am Main 80
Dublin 65
Jacksonville 60
Ashburn 57
Houston 48
Dearborn 44
Seattle 33
Milan 31
New York 27
Cambridge 23
Nanjing 23
Princeton 20
Göttingen 18
Hong Kong 18
Brussels 15
Shanghai 12
Lachine 10
Fremont 9
Guangzhou 9
Altamura 8
Lawrence 8
Nanchang 8
Shenyang 8
Beijing 6
Fürstenwalde 6
Pune 6
Tianjin 6
Edmonton 5
Helsinki 5
Kiev 5
Toronto 5
Gorgonzola 4
Jinan 4
Kunming 4
Andover 3
Jiaxing 3
London 3
Munich 3
Boardman 2
Changsha 2
Falls Church 2
Hefei 2
Huizen 2
Langfang 2
Monmouth Junction 2
Mountain View 2
Nürnberg 2
Quartucciu 2
Redmond 2
Rovellasca 2
San Diego 2
Trieste 2
Zanjan 2
Adliswil 1
Americana 1
Amsterdam 1
Auckland 1
Belgrade 1
Buffalo 1
Cairo 1
Central 1
Chicago 1
Duncan 1
Hangzhou 1
Kuala Lumpur 1
Leawood 1
Levico Terme 1
Lisbon 1
Luxembourg 1
Madrid 1
Norwalk 1
Oslo 1
Otley 1
Ottawa 1
Perugia 1
Philadelphia 1
Piemonte 1
Ripalta Cremasca 1
Robbio 1
Sacramento 1
San Francisco 1
San Mateo 1
Stockholm 1
Trento 1
Walnut 1
Wuhan 1
Zhangzhou 1
Totale 1.543
Nome #
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 286
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 285
Imatinib long term effects study: three years of follow-up and assessment 253
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 247
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 220
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 189
Inhibition of RET tyrosine kinase by SU5416 175
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 174
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins 118
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 116
Totale 2.063
Categoria #
all - tutte 5.118
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.118


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201957 0 0 0 0 0 0 0 0 0 0 27 30
2019/2020458 39 31 34 28 39 51 75 37 49 35 35 5
2020/2021446 13 21 56 49 47 100 40 49 47 19 2 3
2021/2022149 5 12 18 8 7 17 7 4 5 18 15 33
2022/2023325 32 98 37 30 16 39 0 24 14 1 15 19
2023/2024200 11 10 14 19 28 60 36 9 13 0 0 0
Totale 2.063